Commodore Capital’s Avalo Therapeutics AVTX Stock Holding History

Commodore Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.21M	Hold	483,000	–	–	0.42%	33
2025 Q4	$8.77M	Hold	483,000	–	–	0.58%	30
2025 Q3	$6.14M	Hold	483,000	–	–	0.3%	35
2025 Q2	$2.41M	Hold	483,000	–	–	0.17%	33
2025 Q1	$3.87M	Hold	483,000	–	–	0.29%	31
2024 Q4	$3.59M	Hold	483,000	–	–	0.26%	29
2024 Q3	$4.59M	Buy	483,000 +443,000	+1,108%	+$4.57M	0.29%	36
2024 Q2	$499K	Buy	+40,000	New	+$519K	0.03%	35

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Commodore Capital's AVTX Position: Q1 2026 in Review

Commodore Capital held its Avalo Therapeutics (AVTX) position steady in Q1 2026 at 483,000 shares worth $7.21M. The position accounts for 0.42% of the portfolio, ranked #33.

Commodore Capital first reported a position in AVTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.77M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

Commodore Capital held 483,000 shares of Avalo Therapeutics worth $7.21M as of Q1 2026.
Commodore Capital left its Avalo Therapeutics share count unchanged in Q1 2026.
Avalo Therapeutics made up 0.42% of Commodore Capital's portfolio in Q1 2026, its #33 holding.
Commodore Capital first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 8 quarters since.
Commodore Capital's Avalo Therapeutics position peaked at $8.77M in Q4 2025.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.